Jens Markus Borghardt

Dr. Jens Markus Borghardt

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2018 in Canadian Respiratory Journal
Verified
Journal Article
Open access
PDF file
JBJens Markus Borghardt
Jens Markus Borghardt
CKCharlotte Kloft
Charlotte Kloft
ASAshish Sharma
Ashish Sharma
The inhalation route is frequently used to administer drugs for the management of respiratory diseases such as asthma or chronic obstructive pulmonary disease. Compared with other routes of administration, inhalation offers a number of advantages in the treatment of these diseases. For example, via inhalation, a drug is directly delivered to the target organ, conferring high pulmonary drug concentrations and low systemic drug concentrations. Therefore, drug inhalation is typically associated with high pulmonary efficacy and minimal systemic side effects. The lung, as a target, represents an organ with a complex structure and multiple pulmonary-specific pharmacokinetic processes, including (1) drug particle/droplet deposition; (2) pulmonary drug dissolution; (3) mucociliary and macrophage clearance; (4) absorption to lung tissue; (5) pulmonary tissue retention and tissue metabolism; and (6) absorptive drug clearance to the systemic perfusion. In this review, we describe these pharmacokinetic processes and explain how they may be influenced by drug-, formulation- and device-, and patient-related factors. Furthermore, we highlight the complex interplay between these processes and describe, using the examples of inhaled albuterol, fluticasone propionate, budesonide, and olodaterol, how various sequential or parallel pulmonary processes should be considered in order to comprehend the pulmonary fate of inhaled drugs.

7 April 2015 in The AAPS Journal
Verified
Journal Article
Closed access
JBJens Markus Borghardt
Jens Markus Borghardt
BWBenjamin Weber
Benjamin Weber
ASAlexander Staab
Alexander Staab
CKCharlotte Kloft
Charlotte Kloft

8 September 2015 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
JBJens Markus Borghardt
Jens Markus Borghardt
BWBenjamin Weber
Benjamin Weber
ASAlexander Staab
Alexander Staab
CKChristina Kunz
Christina Kunz
SFStephan Formella
Stephan Formella
CKCharlotte Kloft
Charlotte Kloft
Aims: Olodaterol, a novel β2‐adrenergic receptor agonist, is a long‐acting, once‐daily inhaled bronchodilator approved for the treatment of chronic obstructive pulmonary disease. The aim of the present study was to describe the plasma and urine pharmacokinetics of olodaterol after intravenous administration and oral inhalation in healthy volunteers by population pharmacokinetic modelling and thereby to infer its pulmonary fate.Methods: Plasma and urine data after intravenous administration (0.5–25 μg) and oral inhalation (2.5–70 μg via the Respimat® inhaler) were available from a total of 148 healthy volunteers (single and multiple dosing). A stepwise model building approach was applied, using population pharmacokinetic modelling. Systemic disposition parameters were fixed to estimates obtained from intravenous data when modelling data after inhalation.Results: A pharmacokinetic model, including three depot compartments with associated parallel first‐order absorption processes (pulmonary model) on top of a four‐compartment body model (systemic disposition model), was found to describe the data the best. The dose reaching the lung (pulmonary bioavailable fraction) was estimated to be 49.4% [95% confidence interval (CI) 46.1, 52.7%] of the dose released from the device. A large proportion of the pulmonary bioavailable fraction [70.1% (95% CI 66.8, 73.3%)] was absorbed with a half‐life of 21.8 h (95% CI 19.7, 24.4 h).Conclusions: The plasma and urine pharmacokinetics of olodaterol after intravenous administration and oral inhalation in healthy volunteers were adequately described. The key finding was that a high proportion of the pulmonary bioavailable fraction had an extended pulmonary residence time. This finding was not expected based on the physicochemical properties of olodaterol.

1 August 2016 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
KLKathrin Locher
Kathrin Locher
JBJens Markus Borghardt
Jens Markus Borghardt
KFKerstin J. Frank
Kerstin J. Frank
CKCharlotte Kloft
Charlotte Kloft
Karl G. WagnerKarl G. Wagner
Karl G. Wagner

3 September 2023 in Drug Discovery Today
Verified
Journal Article
Closed access
CTChristofer S Tautermann
Christofer S Tautermann
JBJens Markus Borghardt
Jens Markus Borghardt
RPRoland Pfau
Roland Pfau
MZMatthias Zentgraf
Matthias Zentgraf
NWNils Weskamp
Nils Weskamp
ASAchim Sauer
Achim Sauer

23 June 2016 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
JBJens Markus Borghardt
Jens Markus Borghardt
BWBenjamin Weber
Benjamin Weber
ASAlexander Staab
Alexander Staab
CKChristina Kunz
Christina Kunz
CKCharlotte Kloft
Charlotte Kloft